(PINKSHEETS: KKUR) on the Front Line of Cancer Detection
November 18 2009 - 1:33PM
Marketwired
ChromoCure, Inc. (PINKSHEETS: KKUR) announced recently its
nationwide diagnostic lab partnership program to increase awareness
of its CS200 Chromosomal Scanner, its leading cancer detection
system.
ChromoCure's research demonstrates and confirms the 100% common
chromosomal condition present in every form of cancer. By detecting
this unique chromosomal condition the Company's ability to detect
cancer, of all types and stages, is effectively 100% accurate.
ChromoCure indicates they have the ability to completely eliminate
false positives and false negatives for the presence of cancer.
ChromoCure believes its CS200 Chromosomal Scanner employs the
fastest, most accurate method of detecting cancer in tissue samples
by testing for cancer's unique chromosomal imbalance. The company's
research and scientific literature both support this imbalance as
the most accurate predictor of cancer available in today's market.
The company does not believe any cancer technology exists that uses
cancer's unique chromosomal condition combined with automated cell
nucleus scanning.
ChromoCure is positioning itself in the $16.8 billion dollar
cancer detection and therapy market by offering its CS200
Chromosomal Scanner and soon to be released CS300 Scanner free to
all participating pathology labs along with training, materials and
marketing guidance.
The Company also has certain initiatives underway to apply its
understanding of cancer to both therapeutic technologies and
possible cure.
Other active stocks are Biocentric Energy Holdings (PINKSHEETS:
BEHL), Hologic (NASDAQ: HOLX), C.R. Bard, Inc. (NYSE: BCR).
Information, opinions and analysis contained herein are based on
sources believed to be reliable, but no representation, expressed
or implied, is made as to its accuracy, completeness or
correctness. The opinions contained herein reflect our current
judgment and are subject to change without notice. We accept no
liability for any losses arising from an investor's reliance on or
use of this report. This report is for information purposes only,
and is neither a solicitation to buy nor an offer to sell
securities. A third party has hired and paid IO News Wire twelve
hundred and ninety five dollars for the publication and circulation
of this news release. Certain information included herein is
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995, including, but not limited to,
statements concerning manufacturing, marketing, growth, and
expansion. Such forward-looking information involves important
risks and uncertainties that could affect actual results and cause
them to differ materially from expectations expressed herein. We
have no ownership of equity, no representation; do no trading of
any kind and send No Faxes or emails.
Contact: Eric Jensen www.ionewswire.com 516.942.4910
Biocentric Energy (CE) (USOTC:BEHL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biocentric Energy (CE) (USOTC:BEHL)
Historical Stock Chart
From Jul 2023 to Jul 2024